RNA helicase signaling is critical for type I interferon production and protection against rift valley fever virus during mucosal challenge

Journal of Virology

Volumn 87, Issue 9, 2013, Pages 4846-4860

  Ermler, Megan E ^a   Yerukhim, Ekaterina ^a   Schriewer, Jill ^b   Schattgen, Stefan ^c   Traylor, Zachary ^a   Wespiser, Adam R ^c   Caffrey, Daniel R ^c   Chen, Zhijian J ^d   King, Charles H ^a   Gale Michael, Jr ^e   Colonna, Marco ^f   Fitzgerald, Katherine A ^c   Buller, R Mark L ^b   Hise, Amy G ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; INTERFERON; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; RNA HELICASE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; ENZYME ACTIVITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RIFT VALLEY FEVER; SIGNAL TRANSDUCTION; VIRUS LOAD;

ANIMALS; CELL LINE; DEAD-BOX RNA HELICASES; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-BETA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOUS MEMBRANE; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

RIFT VALLEY FEVER VIRUS; RNA VIRUSES;

EID: 84876322220     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01997-12     Document Type: Article

References (71)

1. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. 2010. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics, and prevention. Vet. Res. 41:61.
2. Daubney RHJ, Garnham PC. 1931. An undescribed virus disease of sheep, cattle, and man from East Africa. J. Pathol. Bacteriol. 34:545- 579.
3. Carroll SA, Reynes JM, Khristova ML, Andriamandimby SF, Rollin PE, Nichol ST. 2011. Genetic evidence for Rift Valley fever outbreaks in Madagascar resulting from virus introductions from the East African mainland rather than enzootic maintenance. J. Virol. 85:6162- 6167.
4. Shoemaker T, Boulianne C, Vincent MJ, Pezzanite L, Al-Qahtani MM, Al-Mazrou Y, Khan AS, Rollin PE, Swanepoel R, Ksiazek TG, Nichol ST. 2002. Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg. Infect. Dis. 8:1415-1420.
5. Anyamba A, Linthicum KJ, Small J, Britch SC, Pak E, de La Rocque S, Formenty P, Hightower AW, Breiman RF, Chretien JP, Tucker CJ, Schnabel D, Sang R, Haagsma K, Latham M, Lewandowski HB, Magdi SO, Mohamed MA, Nguku PM, Reynes JM, Swanepoel R. 2010. Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006-2008 and possible vector control strategies. Am. J. Trop. Med. Hyg. 83:43-51.
6. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL. 1986. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antivir. Res. 6:285-297.
7. Morrill JC, Jennings GB, Cosgriff TM, Gibbs PH, Peters CJ. 1989. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev. Infect. Dis. 11(Suppl 4):S815-S825.
8. Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J, Huerre M, Haller O. 2001. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J. Virol. 75:1371-1377.
9. Kawai T, Akira S. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 1143:1-20.
10. Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, Pierson TC. 2006. West Nile virus discriminates between DC-SIGN and DCSIGNR for cellular attachment and infection. J. Virol. 80:1290 - 1301.
11. Klimstra WB, Nangle EM, Smith MS, Yurochko AD, Ryman KD. 2003. DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J. Virol. 77:12022-12032.
12. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ. 2008. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood 111:4245- 4253.
13. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. 2009. Activation of innate immune antiviral responses by Nod2. Nat. Immunol. 10:1073-U49.
14. Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, Taxman DJ, Guthrie EH, Pickles RJ, Ting JPY. 2009. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30:556 -565.
15. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. 2009. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med. 206:79-87.
16. Rathinam VAK, Jiang ZZ, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung V, Vogel SN, Szomolanyi-Tsuda E, Fitzgerald KA. 2010. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11:395- 403.
17. Segovia J, Sabbah A, Mgbemena V, Tsai SY, Chang TH, Berton MT, Morris IR, Allen IC, Ting JPY, Bose S. 2012. TLR2/MyD88/NF-κB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection. PLoS One 7:e29695. doi:10.1371/journal.pone.0029695.
18. West AP, Koblansky AA, Ghosh S. 2006. Recognition and signaling by Toll-like receptors. Annu. Rev. Cell Dev. Biol. 22:409-437.
19. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. 2006. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol. 177:6584-6587.
20. Bauer S, Bathke B, Lauterbach H, Patzold J, Kassub R, Luber CA, Schlatter B, Hamm S, Chaplin P, Suter M, Hochrein H. 2010. A major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC? Proc. Natl. Acad. Sci. U. S. A. 107:E139 -E139.
21. Martinez J, Huang XP, Yang YP. 2010. Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA. Proc. Natl. Acad. Sci. U. S. A. 107:6442- 6447.
22. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez- Sobrido L, Akira S, Gill MA, Garcia-Sastre A, Katze MG, Gale M, Jr. 2008. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82:335-345.
23. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, Janke M, Mihailovic A, Wardle G, Juranek S, Kato H, Kawai T, Poeck H, Fitzgerald KA, Takeuchi O, Akira S, Tuschl T, Latz E, Ludwig J, Hartmann G. 2009. Recognition of 5= triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31:25-34.
24. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. 2006. 5=-Triphosphate RNA is the ligand for RIG-I. Science 314:994 -997.
25. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS, Colonna M. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. U. S. A. 103:8459 - 8464.
26. Pichlmair A, Schulz O, Tan CP, Rehwinkel J, Kato H, Takeuchi O, Akira S, Way M, Schiavo G, Reise Sousa C. 2009. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol. 83:10761-10769.
27. Komuro A, Bamming D, Horvath CM. 2008. Negative regulation of cytoplasmic RNA-mediated antiviral signaling. Cytokine 43:350 - 358.
28. Xagorari A, Chlichlia K. 2008. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol. J. 2:49 -59.
29. Satoh T, Kato H, Kumagai Y, Yoneyama M, Sato S, Matsushita K, Tsujimura T, Fujita T, Akira S, Takeuchi O. 2010. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc. Natl. Acad. Sci. U. S. A. 107:1512-1517.
30. Rothenfusser S, Goutagny N, DiPerna G, Gong M, Monks BG, Schoenemeyer A, Yamamoto M, Akira S, Fitzgerald KA. 2005. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J. Immunol. 175:5260 -5268.
31. Habjan M, Andersson I, Klingstrom J, Schumann M, Martin A, Zimmermann P, Wagner V, Pichlmair A, Schneider U, Muhlberger E, Mirazimi A, Weber F. 2008. Processing of genome 5= termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS One 3:e2032. doi:10.1371/journal.pone.0002032.
32. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413:732-738.
33. Funami K, Matsumoto M, Oshiumi H, Akazawa T, Yamamoto A, Seya T. 2004. The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. Int. Immunol. 16:1143- 1154.
34. Wang J, Shao Y, Bennett TA, Shankar RA, Wightman PD, Reddy LG. 2006. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J. Biol. Chem. 281:37427-37434.
35. Caplen H, Peters CJ, Bishop DH. 1985. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66(Pt 10):2271-2277.
36. Ikegami T, Won S, Peters CJ, Makino S. 2006. Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J. Virol. 80:2933-2940.
37. Liu YC, Gray RC, Hardy GAD, Kuchtey J, Abbott DW, Emancipator SN, Harding CV. 2010. CpG-B oligodeoxynucleotides inhibit TLRdependent and -independent induction of type I IFN in dendritic cells. J. Immunol. 184:3367-3376.
38. Pecora ND, Fulton SA, Reba SM, Drage MG, Simmons DP, Urankar-Nagy NJ, Boom WH, Harding CV. 2009. Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection. Cell. Immunol. 254:94 -104.
39. Qu Y, Ramachandra L, Mohr S, Franchi L, Harding CV, Nunez G, Dubyak GR. 2009. P2X7 receptor-stimulated secretion of MHC class II-containing exosomes requires the ASC/NLRP3 inflammasome but is independent of caspase-1. J. Immunol. 182:5052-5062.
40. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O'Neill LA. 2001. Mal (MyD88-adapterlike) is required for Toll-like receptor-4 signal transduction. Nature 413: 78-83.
41. Ablasser A, Poeck H, Anz D, Berger M, Schlee M, Kim S, Bourquin C, Goutagny N, Jiang Z, Fitzgerald KA, Rothenfusser S, Endres S, Hartmann G, Hornung V. 2009. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J. Immunol. 182: 6824-6833.
42. Le May N, Mansuroglu Z, Leger P, Josse T, Blot G, Billecocq A, Flick R, Jacob Y, Bonnefoy E, Bouloy M. 2008. A SAP30 complex inhibits IFN-β expression in Rift Valley fever virus-infected cells. PLoS Pathog. 4:e13. doi:10.1371/journal.ppat.0040013.
43. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reise Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101-105.
44. Medzhitov R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1:135-145.
45. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. 2006. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 80:5059 -5064.
46. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. 2000. Pattern recognition receptors TLR4 and CD14 mediate response torespiratory syncytial virus. Nat. Immunol. 1:398-401.
47. Lagos D, Vart RJ, Gratrix F, Westrop SJ, Emuss V, Wong PP, Robey R, Imami N, Bower M, Gotch F, Boshoff C. 2008. Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe 4:470-483.
48. Okumura A, Pitha PM, Yoshimura A, Harty RN. 2010. Interaction between Ebola virus glycoprotein and host Toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J. Virol. 84: 27-33.
49. LaBeaud AD, Muchiri EM, Ndzovu M, Mwanje MT, Muiruri S, Peters CJ, King CH. 2008. Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya. Emerg. Infect. Dis. 14:1240 -1246.
50. Colonna M, Krug A, Cella M. 2002. Interferon-producing cells: on the front line in immune responses against pathogens. Curr. Opin. Immunol. 14:373-379.
51. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S. 2005. Cell typespecific involvement of RIG-I in antiviral response. Immunity 23:19-28.
52. Luber CA, Cox J, Lauterbach H, Fancke B, Selbach M, Tschopp J, Akira S, Wiegand M, Hochrein H, O'Keeffe M, Mann M. 2010. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 32:279 -289.
53. Hoshino K, Kaisho T. 2008. Nucleic acid sensing Toll-like receptors in dendritic cells. Curr. Opin. Immunol. 20:408-413.
54. Lozach PY, Kuhbacher A, Meier R, Mancini R, Bitto D, Bouloy M, Helenius A. 2011. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 10:75- 88.
55. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, Gstaiger M, Superti-Furga G, Unger H, Weber F. 2009. NSs protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNAdependent protein kinase. J. Virol. 83:4365- 4375.
56. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S. 2009. Rift Valley fever virus NSs protein promotes posttranscriptional downregulation of protein kinase PKR and inhibits eIF2α phosphorylation. PLoS Pathog. 5:e1000287. doi:10.1371/journal.ppat.1000287.
57. Le May N, Dubaele S, Proietti De Santis L, Billecocq A, Bouloy M, Egly JM. 2004. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116:541-550.
58. LaBeaud AD, Muiruri S, Sutherland LJ, Dahir S, Gildengorin G, Morrill J, Muchiri EM, Peters CJ, King CH. 2011. Postepidemic analysis of Rift Valley fever virus transmission in northeastern Kenya: a village cohort study. PLoS Negl. Trop. Dis. 5:e1265. doi:10.1371 /journal.pntd.0001265.
59. Geisbert TW, Jahrling PB. 2004. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10:S110 -S121.
60. Outinen TK, Makela SM, Ala-Houhala IO, Huhtala HSA, Hurme M, Paakkala AS, Porsti IH, Syrjanen JT, Mustonen JT. 2010. The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations. BMC Infect. Dis. 10:132-139. doi:10.1186/1471-2334-10-132.
61. Pollari E, Savchenko E, Jaronen M, Kanninen K, Malm T, Wojciechowski S, Ahtoniemi T, Goldsteins G, Giniatullina R, Giniatullin R, Koistinaho J, Magga J. 2011. Granulocyte colony-stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J. Neuroinflamm. 8:74-87.
62. Hermesh T, Moran TM, Jain D, Lopez CB. 2012. Granulocyte colonystimulating factor protects mice during respiratory virus infections. PLoS One 7:e37334. doi:10.1371/journal.pone.0037334.
63. Muse M, Kane JAC, Carr DJJ, Farber JM, Lane TE. 2008. Insertion of the CXC chemokine ligand 9 (CXCL9) into the mouse hepatitis virus genome results in protection from viral-induced encephalitis and hepatitis. Virology 382:132-144.
64. Mosser DM, Zhang X. 2008. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226:205-218.
65. Tang-Feldman YJ, Lochhead GR, Lochhead SR, Yu C, Pomeroy C. 2011. Interleukin-10 repletion suppresses proinflammatory cytokines and decreases liver pathology without altering viral replication in murine cy- tomegalovirus (MCMV)-infected IL-10 knockout mice. Inflamm. Res. 60: 233-243.
66. Deshmane SL, Kremlev S, Amini S, Sawaya BE. 2009. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29:313-326.
67. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M. 2008. Establishment and maintenance of the innate antiviral response to west nile virus involves both RIG-I and MDA5 signaling through IPS-1. J. Virol. 82:609 - 616.
68. Nasirudeen AMA, Wong HH, Thien PL, Xu SL, Lam KP, Liu DX. 2011. RIG-I, MDA5, and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl. Trop. D 5:e926. doi:10.1371 /journal.pntd.0000926.
69. Peters CJ AGJ. 1981. Pathogenesis of Rift Valley fever. Contrib. Epidemiol. Biostat. 3:21- 41.
70. Anderson GW, Jr, Slone TW, Jr, Peters CJ. 1987. Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb. Pathog. 2:283-293.
71. Ritter M, Bouloy M, Vialat P, Janzen C, Haller O, Frese M. 2000. Resistance to Rift Valley fever virus in Rattus norvegicus: genetic variability within certain 'inbred' strains. J. Gen. Virol. 81:2683-2688.